AbbVie

Patient Support Services Guide 2018


Abbvie.com
888-249-4918

Co-pay Card Assistance Program
855-692-6729

AbbVie, together with Genentech, has developed and is marketing the oncology drug Venclexta (venetoclax). Venclexta is indicated for patients with chronic lymphocytic leukemia and 17p deletion who have received at least 1 previous treatment (Table).

AbbVie, together with Genentech, offers patients prescribed Venclexta multiple avenues of financial assistance, including:

BioOncology Co-pay Card for Venclexta, which assists with out-of-pocket costs for commercially insured patients.

Genentech Access to Care Foundation, which, for uninsured and underinsured patients, may be able to provide Venclexta to eligible patients for free.

Venclexta Access Solutions, which offers insured (commercial and government) and uninsured patients referrals to copay assistance programs.

Eligibility

BioOncology Co-pay Card for Venclexta

Qualifying patients pay $25 per prescription, with an annual benefit limit of up to $25,000.

To be eligible to receive Venclexta, patients must:

  • Have commercial insurance (private or nongovernmental); this is not valid for patients with government insurance or whose medications are covered, in whole or in part, by state-funded or federally funded healthcare programs
  • Reside in and receive treatment in the United States or Puerto Rico
  • Be aged ≥18 years
  • Use Venclexta for an FDA-approved indication
  • Must not be uninsured or currently participating in the Genentech Access to Care Foundation.

Patients should request copay assistance within 120 days of receiving a Venclexta prescription. For more information, contact 855-692-6729 or visit CopayAssistanceNow.com.

Genentech Access to Care Foundation

To be eligible for Genentech Access to Care Foundation assistance, patients must meet the following criteria:

  • Patients must enroll in Venclexta Access­Solutions
  • For uninsured patients, their annual income should be ≤$100,000, or $100,001 to $150,000 and ≥5% out-of-pocket expenses on medication
  • For insured patients, their annual income should be ≤$150,000 and ≥5% out-of-pocket expenses on medication
  • Patients must have failed previous attempts to obtain copay assistance from other resources.

To learn more about the programs and services, visit Genentech-Access.com/VENCLEXTA or call 888-249-4918.

Application & Enrollment

BioOncology Co-pay Card for Venclexta

Enrollment requires completion and submission of an eligibility form, available at CopayAssistanceNow.com. Patients may also call 855-692-6729.

Venclexta Access Solutions

To avail of the services provided by this program, submission of the following 2 forms is required:

  1. The Patient Authorization and Notice of Request for Transmission of Health Information to Genentech Access Solutions and Genentech Access to Care Foundation
  2. The Statement of Medical Necessity, available online.

Upon enrollment, the service collaborates with patients, physicians, and/or insurance before providing assistance options.

Genentech Access to Care Foundation

Enrollment in Genentech Access to Care Foundation requires enrollment in Venclexta Access Solutions, with completion of sections 5 and 6 in the Patient Authorization and Notice of Request for Transmission of Health Information to Genentech Access Solutions and Genentech Access to Care Foundation form.

Other Services

The Venclexta SureStart Program allows patients facing coverage delays to begin treatment with Venclexta until a coverage decision is made. To be eligible for this program, patients must:

  • Have a prescription for Venclexta for an approved indication
  • Have received no initial prior authorization or coverage decision within 5 business days.

If coverage decision is pending, shipments can continue for up to 90 days.

Oncology nurses provide patient support through the VENCOMPASS program, including reminders about medications and appointments, recognizing treatment-related issues, answering medication-related questions, and informing patients about organizations that provide additional support.

AbbVie Oncology Drug

Drug
Indication
Patient support programs

Drug
Venclexta (venetoclax)
Indication
Chronic lymphocytic leukemia with deletion 17p after ≥1 previous therapies